Aldeyra Therapeutics
ALDX
112 hedge funds and large institutions have $196M invested in Aldeyra Therapeutics in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 24 reducing their positions, and 8 closing their positions.
164% more call options, than puts
Call options by funds: $2.18M | Put options by funds: $825K
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
71% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 24
68% more capital invested
Capital invested by funds: $117M → $196M (+$79.5M)
9% more funds holding
Funds holding: 103 → 112 (+9)
2.29% more ownership
Funds ownership: 59.47% → 61.76% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
Top Sellers
ALDX Hedge Fund Activity: Q3 2024 in Review
112 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q3 2024, worth a combined $196M — up 68% from $117M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ALDX positions and 8 closed out — a net gain of 10 holders — while 41 added to existing stakes and 24 trimmed.
The largest buyer was Invesco, adding an estimated $2.98M. The largest seller was Renaissance Technologies, cutting an estimated $1.88M.
- 112 institutional investors held Aldeyra Therapeutics (ALDX) as of Q3 2024, up from 103 in Q2 2024.
- Funds reported $196M of Aldeyra Therapeutics stock for Q3 2024, up 68% quarter-over-quarter.
- 18 funds opened new Aldeyra Therapeutics positions in Q3 2024 and 8 closed out, a net change of +10 holders.
- The largest Aldeyra Therapeutics buyer in Q3 2024 was Invesco, an estimated $2.98M added.
- The largest Aldeyra Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $1.88M sold.
Based on aggregated 13F filings for Q3 2024.